Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial. In Onkológia. ISSN 1336-8176. Bratislava : SOLEN, 2017, 2017, roč. 12, č. 6, s. 453.